CONTINEUM THERAPEUTICS INC

Inside view: CONTINEUM’s chief scientist buys 28,826 shares at $1.01, reinforcing a bullish insider stance amid a strong rally and 21.97% monthly gain.

Insider trades at Contineum Therapeutics show disciplined 10‑b‑1 plans, revealing long‑term commitment amid potential dilution and milestone‑driven growth.

Contineum Therapeutics insider sales reveal strategic selling by CSO Lorrain Daniel S. amid Phase 1b gains, showing disciplined moves that may temper short‑term enthusiasm but keep long‑term growth upside.

Insider 10b5‑1 trades by Contineum’s CSO show confidence in its growing pipeline—small buys at $1.01 and sells at $16 signal strategic positioning and risk‑managed growth.

Contineum Therapeutics insider sale: Lorrain Daniel S. sells 4,170 shares at $14.82. Understand why it’s routine, not a red flag, and what it means for investors.